CTDI Volume Measurement of CT Simulation and CT Effective Dose Calculation for Cervix and Prostate
Collections
Abstract
The accurate measurement of Computed Tomography Dose Index (CTDI) volume and the
calculation of effective dose are crucial in optimizing patient safety and ensuring the efficacy
of CT simulations in radiation therapy. This study focuses on evaluating the CTDI volume
during CT simulations and calculating the effective dose for patients undergoing treatment
for cervical and prostate cancers. By using phantoms and patient-specific data, this study
aims to quantify the radiation dose distribution and assess the potential risks associated with
these diagnostic procedures. The present retrospective study was conducted on 53 cervical
and prostate cancer patients (6 prostate and 47 cervical) with ages ranging from 35 to 75
years. The examinations were carried out using a Philips Ingenuity Time-of-Flight (ToF) 64
slice PET/CT system (Philips Healthcare, Cleveland, OH, USA) at the Institute of Nuclear
Medical Physics, Atomic Energy Research Establishment (AERE), Savar, Dhaka. The scans
were performed according to institutional protocols. Dose measurements were carried out in
terms of CTDI100. CTDI100 values for the center and periphery of the phantom were recorded,
and the average value of the periphery doses was taken. Then, CTDIw was calculated using
CTDI100 values. Since an axial CT scan was taken on the phantom, there was no patient table
movement, making CTDIvol values the same as CTDIw values. The mean±SD CTDIvol was
obtained as 18.879±5.914 mGy, ranging from 8.952 to 37.327 mGy. The CT effective doses
were calculated using the dose conversion coefficient k=0.015 mSv.mGy-1.cm-1 for the pelvic
region, as described in the American Association of Physicists in Medicine Report No. 96.
The effective doses for the CT procedure were estimated using DLP values that represent
radiation exposure over the entire scan length. The scan lengths were generated by the
scanner, and the DLP values were measured as the product of CTDIvol and scan length. The
DLP values ranged from 411.225 to 2030.96 mGy·cm, with a mean value of
1094.479±462.029 mGy·cm. The effective dose is the product of the DLP and the conversion
coefficient k. The mean effective dose for the pelvic region was 16.271±7.180 mSv. The
doses for prostate patients were 15.125±8.815 mSv, and for cervical patients, they were
16.417±8.930 mSv. The present study found these values to be moderately higher compared
to the effective dose values of conventional diagnostic radiology examinations. This is
because the CT scans were performed on the patients as part of radiotherapy treatment
planning, and the scan lengths were longer than the pelvic region, resulting in higher effective
doses. However, this study suggests that the risk-benefit ratio of any radiological scan should
be clarified and carefully weighed.
